Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Maintenance Post-HSCT in Ph+ ALL
NCT05024357Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Percentage of Patients with Measurable Residual Disease Positivity at 36 months and Percentage of Patients with Complete Remission at 36 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05024357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024357.